Remove 2006 Remove Pharma Remove Safety
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. You can compare timelines.

Pharma 64
article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. The pandemic raised the sector’s profile and has helped establish pharma as a desirable career path for several reasons, including job security, innovation, and societal value.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RFID: The future of smart labelling?

Pharmaceutical Technology

Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. Various uses soon became apparent including those for supply chain management, anti-counterfeiting, and to improve patient safety.

article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

Pharma companies continue to be among the most profitable industries, even outperforming tech companies. The Pharma Spin. Pharma continues to spin the lie about the high development costs of drugs but an analysis tells us the truth. This is an industry that doesn’t care about what people think of them.

Insurance 181
article thumbnail

The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next

PM360

Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar being approved in Europe in 2006. The entire premise was that because biosimilars were so new, and there was not a lot of information on the safety and efficacy of those products, customers should be a bit leery prior to jumping on the biosimilar bandwagon.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. For this reason, a unique ‘abridged’ procedure was introduced to provide a specific regulatory pathway for biosimilars in the EU.

article thumbnail

Bringing the patient voice into clinical trials with clinical outcome assessments

Clarivate

The purpose of clinical trials is to understand the efficacy and safety of treatments for the patients who need them. In this article, we share how a sponsor partnered with Clarivate to incorporate COAs into clinical trials for alopecia areata. The regulatory landscape around COAs is fast evolving.